GlassScriptPhysician profile
Stephen A Larsen
NPI 1720148604
$8,336.16
in general payments reported to CMS, 2019-2025
29 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $244 · 2021: $1,565 · 2022: $1,333 · 2023: $1,826 · 2024: $1,690 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,827.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $960.44 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $734.72 | 2021-2025 | Rocklatan, Tryptyr, Rhopressa |
| Abbvie INC. | $566.26 | 2022-2025 | |
| Oyster Point Pharma, INC. | $504.34 | 2022-2024 | Tyrvaya |
| Coopervision INC. | $494.84 | 2021-2023 | Myday Contact Lens, Biofinity Contact Lens |
| Novartis Pharmaceuticals Corporation | $470.94 | 2019-2023 | |
| Astellas Pharma US INC | $415.35 | 2023-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $401.27 | 2024-2025 | Xdemvy |
| Genentech USA, INC. | $387.69 | 2022-2024 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $287.12 | 2019-2022 | |
| Biotissue Holdings INC. | $267.57 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $260.96 | 2021-2022 | |
| Glaukos Corporation | $251.78 | 2021-2024 | Ce-Marked Kxla System |
| Regeneron Healthcare Solutions, INC. | $250.73 | 2023 | Eylea, Eylea Hd |
| Aerie Pharmaceuticals, INC. | $228.93 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $220.05 | 2024-2025 | Oxervate |
| Allergan, INC. | $196.30 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $183.29 | 2019-2021 | |
| Rxsight INC | $177.00 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Merz Pharmaceuticals, LLC | $164.33 | 2023 | Xeomin |
| Mallinckrodt Hospital Products INC. | $155.50 | 2022 | |
| Lkc Technologies, INC. | $137.05 | 2024 | |
| Tearlab Corp | $131.50 | 2023 | Tearlab Osmolarity System |
| Sight Sciences, INC. | $127.80 | 2024 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $122.78 | 2021 | |
| Apellis Pharmaceuticals, INC. | $102.60 | 2024 | Syfovre |
| Shire North American Group INC | $62.90 | 2019 | |
| Sun Pharmaceutical Industries INC. | $54.95 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $17.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Larsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.